News & Events

View the various news of Celemics

News & Events

  • [Medica 2021] Celemics Booth Information (10/14/2021) Posted in: EVENT
  • [Promotion] G-Mendeliome Clinical Exome Sequencing (CES) Panel (10/13/2021) Posted in: EVENT
  • Celemics signs a supply agreement for BTSeq™ solution with Chinese Sanger sequencing service company (7/14/2021) Posted in: NEWS

    Celemics signs a supply agreement for BTSeq™ solution with Chinese Sanger sequencing service company

    – Celemics enters the Chinese DNA Sequencing market since its establishment
    – NGS-based BTSeq™ solution allows for highly accurate DNA sequencing with significantly reduced cost and time
    – The agreement scale is equivalent to 87% in celemics’ annual revenue

    July.14.2021, Seoul, Korea: Celemics, Inc.(, an NGS-based sequencing solution and bioinformatics company, Co-CEO Young-hoon Lee and Hyo-ki Kim announced on July 14th
    that Celemics has signed an annual supply agreement to provide 4.5 billion KRW ($3.9 million) worth BTSeq™ solution with Tsingke Biological Technology Co., Ltd. (Tsingke), a professional Beijing-based
    Sanger sequencing and gene synthesis service company.

    The agreement scale is equivalent to 87% of Celemics’ annual sales of 5.2 billion KRW ($4.5 million) in 2020, which is the largest single contract that Celemics has signed since expanding to the
    global market in 2017. Celemics will provide BTSeq™ reagents and analysis software, a proprietary genomics analysis platform, in China to Tsingke.

    Celemics’ technology supplied to Tsingke with this agreement is BTSeq™ (Barcode Tagged Sequencing) which utilizes NGS technology and Celemics’ proprietary sample preparation reagents and
    de novo assembly bioinformatics software. BTSeq™ solution allows for highly accurate DNA sequencing with significantly reduced cost and time. With the conventional method, Sanger sequencing,
    the sequencing of a few kb to 20 kb-long DNA takes several days to a few weeks and requires multiple sequencing runs and primer syntheses with high cost. BTSeq™ overcomes these challenges and
    enables accurate sequencing of 20 kb-long or longer DNA within 24 hours. With Celemics proprietary reagents and bioinformatics, the cost for NGS-based sequencing and the time required for
    analysis is significantly reduced.

    Tsingke, Celemics’ Chinese partner for the Chinese genome analysis market, is a professional DNA synthesis and sequencing company established in 2004. Tsingke has 19 subsidiaries in China,
    including Beijing, Shanghai and Guangzhou and is a large-scale business proceeding with about 15 million DNA synthesis and sequencing cases annually. Tsingke conducted thorough validation with
    various samples in its affiliated companies in Nanjing, Tianjin, etc. to check the BTSeq™ performance and purchased large volume of reagent and analysis software for beta operation.
    After about a year of the rigorous validation period, Tsingke decided to introduce Celemics’ BTSeq™ solution.

    “We expect to secure exclusive competitiveness in DNA synthesis and sequencing service with the new Celemics’ sequencing technology, BTSeq™, and will pioneer diverse application markets with Celemics.”
    ‘Tsingke CEO Ma Shijin’

    “Celemics is delighted to enter the Chinese NGS market through scrupulous examinations, which reassure the competitiveness of BTSeq™. Celemics will take this contract as a stepping stone to expand
    our contribution for researchers and companies in the fast-growing Chinese DNA sequencing market with 1.4 billion population.”
    ‘Celemics Co-Founder & CEO Hyoki Kim’

    Meanwhile, Celemics has been continuously and successfully preparing to expand to the global market. Celemics has recently completed designating distributors in countries such as Spain, Portugal,
    United Arab Emirate (UAE) and Japan and concluded partnership arrangements with distinguished international companies.


  • Celemics, South Dakota State University, announce partnership for the development of Hybridization NGS-based Multiple Swine Pathogen Co-Detection Panel (7/7/2021) Posted in: NEWS

    Genomeweb EINPRESSWIRE

    Celemics, South Dakota State University, announce partnership for the development of Hybridization NGS-based Multiple Swine Pathogen Co-Detection Panel.

    – The proposed methods are seen as a revolutionary step towards preventing swine respiratory diseases

    July 07, 2021, Seoul, Korea: Celemics, Inc.( has partnered with South Dakota State University’s Animal Disease Research and Diagnostic Laboratory (ADRDL) to create the first-ever hybridization-based
    next generation sequencing (NGS) kit to detect viral and bacterial swine respiratory pathogens.

    Most current diagnostic technologies are based on culture or qPCR. These widely used methods come with a great amount of limitations in terms of detecting a wide range of pathogens. The new and proposed breakthrough technique
    can make it possible to detect several viral and bacterial pathogens at once.

    Celemics Inc. is known for its innovative and ground-breaking research. It was the need of the hour to alter the paradigm of medicine for swine respiratory diagnosis and treatment. It is hoped that their much-welcomed partnership with
    the esteemed South Dakota State University will bring revolutionary methods for early detection and cure to the industry.
    Until this point in time, the genetic characterization, including whole genome sequence information for viral pathogens and multi-locus sequencing typing (MLST) analysis for bacterial pathogens, is attained through pathogen detection methods.
    This joint venture of research between the two reputed names has given them hope for improved overall herd health outcomes. The technology aims to overcome the shortfalls of modern diagnostics by enabling highly multiplexed detection
    and sequence characterization.
    Not only would this be more efficient but considerably cost-effective in comparison to the existing practices.

    We spoke to Mr. Benjamin Hause, Assistant Professor in the Department of Veterinary and Biomedical Sciences, about this promising prospect:
    “We are pleased to partner with Celemics on developing and bringing this exciting new technology to the swine industry,” ‘Celemics’ hybridization panel represents a large leap forward in our ability to detect and concurrently
    genetically characterize swine pathogens.
    While we focus on the most significant pathogens such as porcine reproductive and respiratory syndrome virus and influenza A virus, clinical disease is often the end result of co-infections with a number of viruses and bacteria.
    Celemics’ technology will enable comprehensive pathogen screening that will allow better herd management and improved swine health.”
    The technology aims to overcome the shortfalls of modern diagnostics by enabling highly multiplexed detection and sequence characterization. Not only would this be more efficient but considerably cost-effective in comparison to the existing practices.

    The kit results from years of remarkable research and comprises more than 50 different viral and bacterial swine pathogens. All of these sequences have been carefully chosen based on the study of patterns that are relevant to swine health
    and include domestically critical species such as the porcine reproductive and respiratory syndrome virus (PRRSV) and influenza A virus, along with foreign viruses such as African swine fever virus (ASFV) and foot and mouth disease virus.
    “With this new partnership, we hope to provide clinicians, veterinarians, and livestock breeders with a powerful, comprehensive tool for swine disease detection and prevention,” said co-CEO and founder of Celemics, Dr. Hyoki Kim.

    Through the advantages of hybridization NGS, we hope to provide a kit capable of revolutionizing clinical research and diagnostics and hope to effectively combat future swine disease epidemics.


  • [Webinar] Celemics X Strand Life Science Fast Automated Cancer Variant Prioritization & Reporting using stranomics (7/2/2021) Posted in: EVENT
  • Celemics, Strand Life Sciences Partner on Integrated Platform for NGS Analysis (6/15/2021) Posted in: NEWS

    GenomeWeb Microbioz India BioSpectrumasia IndiaMedtoday

    Celemics Partner with Strand Life Science and their StrandOmics Analysis Platform

    – Strand Life Science will provide their StrandOmics analysis platform in conjunction with Celemics bioinformatic pipeline, including assay-specific variant filters with a complete sample-to-report solution.
    – This partnership will help to provide guaranteed clinical-grade data compliance for customers

    June 09, 2021, Seoul Korea: Celemics( co-founder and CEO Dr. Hyoki Kim announced a partnership with Strand Life Sciences, a leading precision medicine informatics company,
    to develop a bioinformatics solution capable of providing users with an accelerated means of producing high-quality, in-class clinical genomics reports and enabling a complete sample-to-answer solution,
    including assay-specific variant filters.

    Under the agreement, Strand Life Science will integrate the Celemics bioinformatics pipeline into the StrandOmics tertiary analysis platform to enable Celemics with a complete sample-to-report solution.
    Leveraging the StrandOmics platform, Celemics plans to serve an expanding global market with clinical-grade data compliance and guaranteed data residency for customers in Europe, Asia, and beyond.

    Celemics Co-Founder and CEO Hyoki Kim said, “We are excited about this new partnership with Strand Life Sciences. Their expertise in the engineering of NGS systems and long track record with the
    instrument and diagnostic companies will be valuable in accelerating our path to market integration.”
    Also, Stand Life Sciences CEO Dr. Ramesh Hariharan said, “With our unique track record of running NGS labs as well as interpretation support for genetic tests, we are excited to partner with Celemics
    to help bring their cancer; inherited cancer, and rare disease panels to the market.”

    Founded in 2000 by academics from the Indian Institute of Science, Strand Life Sciences is a specialized genomics solutions company offering bioinformatics, knowledge-based curation development,
    software, assay design, and clinical research services globally, and also operates a diagnostics reference lab with a focus on genomics and oncology in India.
    Celemics is a biotech company developing and supplying critical enabling solutions in genomics, antibody discovery, medicine, biopharma, microbiome, synthetic biology, and AgBio.
    Founded in 2010, Celemics has focused in the last several years on providing target enrichment panels to Europe and Asia for various applications, including oncology, inherited disease,
    and genetic marker discovery.


  • Breakthrough test kit identifies 39 virus strains including Covid-19 mutations (1/6/2021) Posted in: NEWS


    Celemics Launches Comprehensive Respiratory Virus (CRV) Panel for accurate identification and sequencing of whole respiratory virus genomes

    – A NGS approach to detect 39 strains of 9 common human respiratory viruses including SARS-CoV-2, several other coronaviruses, influenzas, rhinoviruses, and respiratory syncytial virus 

    – Offers fast and reliable multiplexed detection of respiratory pathogens in a single reaction 


    Celemics Inc., a company innovating DNAbased material through novel sequencing technology, announced the launch of its Comprehensive Respiratory Virus (CRV) Panel,
    an optimal Research Use Only (RUO) NGS target enrichment solution covering 9 common human respiratory viruses including SARS-CoV-2. 


    The Celemics CRV Panel includes 39 strains of the 9 most prevalent respiratory viruses including coronaviruses (CoV), influenza virus, adenovirus, bocavirus (hBoV), enterovirus,
    metapneumovirus, parainfluenza virus (hPIV), human rhinovirus (HRV), and respiratory syncytial virus (RSV). Unlike common RT-PCR assays, which detect only one pathogen at a time,
    the NGS-based Celemics CRV Panel is designed to identify, detect, and sequence each pathogen and any present mutations in a single reaction. 


    Celemics has engineered the Celemics CRV Panel to provide flexible and reliable performance. The Celemics CRV Panel shows more than 100X coverage for over 99% of the viral genome,
    offers a hybridization time four times faster than the current standard, and it detects concentrations as low as 100 viral copies per virus, enabling researchers to analyze nasopharyngeal samples,
    which commonly do not yield viral loads of sufficient quantity and quality needed for NGS applications. 


    The Celemics CRV Panel is bundled with a non-cloud based standalone bioinformatics software that enables a complete workflow beginning with library preparation and resulting
    in publication-ready results that are not subject to General Data Protection Regulations (GDPR).


    The Celemics CRV Panel is available for access in the United States, Europe, Latin America, Middle East, Singapore, Malaysia, and Thailand via Celemics’ certified retailers. 


  • New Products Posted to GenomeWeb: Personalis, AutoGen, Celemics, More (12/18/2020) Posted in: NEWS


    Celemics CRV Panel

    Celemics has launched its CRV Panel, a multiplexed, target enrichment panel for next-generation sequencing-based identification of common human respiratory viruses,
    including SARS-CoV-2. The research-use-only assay detects a total of 39 strains of nine viruses including coronaviruses, rhinoviruses, influenzas, and respiratory syncytial viruses.
    The panel is bundled with non-cloud-based bioinformatics software that enables a complete workflow.
    The product is available in the US, Europe, Latin America, the Middle East, Singapore, Malaysia, and Thailand via Celemics’ certified retailers.


  • Celemics bags $800K deal to supply gene expression profilers to Firalis SA (10/28/2020) Posted in: NEWS


    Celemics bags $800K deal to supply gene expression profilers to Firalis SA

    Celemics has signed a $800,000 contract to supply its Next-Generation Sequencing (NGS)-based gene expression profilers for neurodegenerative disease to Firalis S.A., a France-based developer and provider of biomarker diagnostic products.

    Shares of Kosdaq-listed Celemics traded a tad higher in the morning session on Wednesday.


    According to its disclosure on Wednesday, Celemics will provide Firalis with NeuroMICS products for PAXgene/PBMC and Plasma/Saliva until 2022. The deal value represents about 18 percent of Celemics’ revenue last year.


    NeuroMICS™ identifies and quantifies more than 5,000 brain tissue-specific long non-coding RNAs (lncRNAs) in peripheral blood samples that can serve as biomarkers to characterize patients with early-stage neurodegenerative disorders such as Alzheimer`s disease.


    NeuroMICS features high-accuracy results based on Celemics` know-how in manufacturing NGS products for 10 years and its unique rebalancing and target capture technology. It can analyze about 5,000 types of lncRNAs at once, providing a more efficient and cost-effective approach than conventional methods, according to the company.


    NeuroMICS is Celemics` second NGS-based product to be delivered to Firalis after a similar deal over FiMICS, an NGS-based product to quantify cardiac-enriched lncRNAs in 2018.


    The availability of the lncRNA panel opens a window for new therapeutics and personalized medicine tools for diverse diseases, experts say.


  • Celemics: Not All NGS Companies Are the Same (8/24/2020) Posted in: NEWS


    Asia’s first and only proprietary tech-based NGS target capture kit developer

    Celemics develops target capture kits for next-generation sequencing (NGS) applications based on its proprietary molecular cloning technology called MSSIC (Massively Separated and Sequence-Identified Cloning). Target capture kits, which play a key role in NGS technology-based targeted sequencing, are commercially produced by only six companies in the world including Celemics.

    Investment points: 1) rapid NGS market growth; 2) business/overseas expansion

    The global NGS market continues to grow alongside technological advancements and sequencing cost declines. In addition to diagnostics, NGS technology is expected to be used in a wider range of applications including new drug development, microbiome, and seed development. As a result, the size of the global NGS market is projected to grow at a rapid pace from USD6.3bn in 2018 to USD31.4bn (KRW35tr) by 2026.

    Steep market growth, in turn, should lead to stronger demand for target capture kits. Celemics, backed by its advanced technology and services vs. peers, will likely enjoy notable growth in market share going forward. In addition, the company’s expansion into sequencing solutions and overseas markets should pick up pacefrom 2020 with the release of its NGS solution, BTSeq (Barcode-Tagged Sequencing).

    Initiate coverage with BUY and a conservative target price of KRW40,000

    We initiate coverage of Celemics with buy for a target price of KRW40,000. Our target price is based on the present value of the EPS forecast of KRW1,239 for 2022 (reflecting expectations for improvement in operating margins to peer average levels backed by overseas and BTSeq sales) and a target PER of 37.9x (15% discount to the PER average of peers).
    On the first day of listing, Celemics shares gained just 29% vs. the IPO price.

    However, we believe Celemics sets itself apart from other listed domestic NGS companies, as: 1) one of the six companies in the world that have succeeded in the commercialization of target capture kits
    for NGS applications; and 2) a company capable of expanding beyond the domestic market to overseas markets for faster earnings growth.

    Recently-listed US peer Twist Bioscience is currently trading at a market cap of USD3bn (roughly KRW3.6tr),even with the company’s target capture kit-related sales standing at just KRW25.3bn as of 2019.
    Considering the upbeat earnings outlook, Celemics shares appear excessively undervalued at current price levels.


  • Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution (10/15/2019) Posted in: NEWS

    PR Newswire

    Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution

    Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced today the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications.

    To serve as an end-to-end workflow with integrated genomic data analysis, Celemics partnered with BlueBee, an industrial-grade and highly configurable data platform provider, to develop a bioinformatics solution tailored 

    for their assay and end-user experience. 


    Collaborative efforts between these two industry leaders produced the Celemics web solution, offering a new level of accessibility to users of target enrichment NGS assays.

    The Celemics web solution will act as a springboard to propel research towards precision medicine and provide Celemics with an extensible, highly efficient and scalable data strategy poised for growth. 


    The Celemics web solution is a turnkey analytics option, transforming raw data into actionable results as part of the Celemics NGS target enrichment kit portfolio. 

    “Data analysis is a critical workflow area with potential for streamlining,” says Dr. Hyoki Kim, CEO Celemics. “We chose BlueBee to address the data analysis bottleneck for our customers with a platform that fits precisely with our assay.

    The Celemics web solution standardizes the digital end of the workflow, is high-performance, and provides ease of use. This strategic product extension is directly in line with our company mission of accelerating precision medicine, 

    which we are thrilled to make tangible for a global market,” Dr. Kim adds.


    Leveraging BlueBee’s Genomics Platform, Celemics is able to serve an expanding global market with clinical-grade data compliance and guaranteed data residency for customers in Europe, Asia, and beyond. 

    The administrator features of the platform ensure that Celemics remains in complete control of their pipeline and operations. The streamlined user interface enables end-users with any level of expertise to analyze, interpret, 

    and return actionable results from their sequencing workflow. Celemics end-users may also work collaboratively, providing secure, permissioned, and audited access of project data and analyses.


    “We are honored to serve Celemics,” says Hans Cobben, CEO of BlueBee. “The BlueBee Genomics Platform, configured for the Celemics data workflow, will streamline data analysis through insight generation for target enrichment applications, 

    and support market expansion for Celemics. Partnerships like this that bridge the gap between wet-lab and data workflows, are critical to the pursuit of precision medicine,” Cobben adds.